Search

Your search keyword '"Montange, Damien"' showing total 33 results
Start Over Author "Montange, Damien"
33 results on '"Montange, Damien"'

5. Circulating cell-free DNA in patients with alveolar echinococcosis

Author

Felix, Sophie, Heyd, Bruno, Mantion, Georges, Di Martino, Vincent, Montange, Damien, Vanlemmens, Claire, Vuitton, Dominique Angèle, Weil-Verhoeven, Delphine, Chavanet, Pascal, Dalle, Frédéric, Gohier, Sandrine, Minello, Anne, Piroth, Lionel, Dumortier, Jérôme, Mabrut, Jean-Yves, Wallon, Martine, Frentiu, Emilia, Machouart, Marie, Watelet, Jérôme, Chemla, Cathy, Feron, Thomas, Heurge-Berlot, Alexandra, Sommacale, Daniele, Thiefin, Gerard, Abou-Bacar, Ahmed, Brunet, Julie, Candolfi, Ermano, Hansmann, Yves, Lefebvre, Nicolas, Baraquin, Alice, Hervouet, Eric, Richou, Carine, Flori, Pierre, Peixoto, Paul, Azizi, Amel, Delabrousse, Eric, Blagosklonov, Oleg, Umhang, Gerald, Bresson-Hadni, Solange, Valot, Benoit, and Grenouillet, Frédéric

Published
2018
Full Text
View/download PDF

16. Circulating cell-free DNA in patients with alveolar echinococcosis

Author

Baraquin, Alice, primary, Hervouet, Eric, additional, Richou, Carine, additional, Flori, Pierre, additional, Peixoto, Paul, additional, Azizi, Amel, additional, Delabrousse, Eric, additional, Blagosklonov, Oleg, additional, Umhang, Gerald, additional, Bresson-Hadni, Solange, additional, Valot, Benoit, additional, Grenouillet, Frédéric, additional, Felix, Sophie, additional, Heyd, Bruno, additional, Mantion, Georges, additional, Di Martino, Vincent, additional, Montange, Damien, additional, Vanlemmens, Claire, additional, Vuitton, Dominique Angèle, additional, Weil-Verhoeven, Delphine, additional, Chavanet, Pascal, additional, Dalle, Frédéric, additional, Gohier, Sandrine, additional, Minello, Anne, additional, Piroth, Lionel, additional, Dumortier, Jérôme, additional, Mabrut, Jean-Yves, additional, Wallon, Martine, additional, Frentiu, Emilia, additional, Machouart, Marie, additional, Watelet, Jérôme, additional, Chemla, Cathy, additional, Feron, Thomas, additional, Heurge-Berlot, Alexandra, additional, Sommacale, Daniele, additional, Thiefin, Gerard, additional, Abou-Bacar, Ahmed, additional, Brunet, Julie, additional, Candolfi, Ermano, additional, Hansmann, Yves, additional, and Lefebvre, Nicolas, additional

Published
2018
Full Text
View/download PDF

17. Exploring venlafaxine pharmacokinetic variability with a phenotyping approach, a multicentric french-swiss study (MARVEL study)

Author

Lloret-Linares, Célia, primary, Daali, Youssef, additional, Chevret, Sylvie, additional, Nieto, Isabelle, additional, Molière, Fanny, additional, Courtet, Philippe, additional, Galtier, Florence, additional, Richieri, Raphaëlle-Marie, additional, Morange, Sophie, additional, Llorca, Pierre-Michel, additional, El-Hage, Wissam, additional, Desmidt, Thomas, additional, Haesebaert, Frédéric, additional, Vignaud, Philippe, additional, Holtzmann, Jerôme, additional, Cracowski, Jean-Luc, additional, Leboyer, Marion, additional, Yrondi, Antoine, additional, Calvas, Fabienne, additional, Yon, Liova, additional, Le Corvoisier, Philippe, additional, Doumy, Olivier, additional, Heron, Kyle, additional, Montange, Damien, additional, Davani, Siamak, additional, Déglon, Julien, additional, Besson, Marie, additional, Desmeules, Jules, additional, Haffen, Emmanuel, additional, and Bellivier, Frank, additional

Published
2017
Full Text
View/download PDF

20. Comparisons of detergents for purification of platelet membrane lipid rafts: a lipidomics and proteomics analysis focusing on P2XR localization

Author

Rabani, Vahideh, Gambert, Ségolène, Davani, Siamak, Montange, Damien, Marqueurs pronostiques et facteurs de régulations des pathologies cardiaques et vasculaires - UFC ( EA 3920) (PCVP / CARDIO), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Université de Franche-Comté (UFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre des Sciences du Goût et de l'Alimentation [Dijon] (CSGA), Institut National de la Recherche Agronomique (INRA)-Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Laboratoire Chrono-environnement - UFC (UMR 6249) (LCE), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Marqueurs pronostiques et facteurs de régulations des pathologies cardiaques et vasculaires - UFC ( PCVP / CARDIO ), Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ) -Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ), Centre des Sciences du Goût et de l'Alimentation [Dijon] ( CSGA ), Institut National de la Recherche Agronomique ( INRA ) -Université de Bourgogne ( UB ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique ( CNRS ), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Laboratoire Chrono-environnement ( LCE ), Université Bourgogne Franche-Comté ( UBFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC ), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre National de la Recherche Scientifique (CNRS)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Institut National de la Recherche Agronomique (INRA)-Université de Bourgogne (UB), and ProdInra, Archive Ouverte

Subjects
[SDV.SP] Life Sciences [q-bio]/Pharmaceutical sciences, [SDV.AEN] Life Sciences [q-bio]/Food and Nutrition, [ SDV.SP ] Life Sciences [q-bio]/Pharmaceutical sciences, [ SDV.AEN ] Life Sciences [q-bio]/Food and Nutrition, [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition
Abstract

Introduction: Platelet membrane contains cholesterol and sphingomyelin-rich microdomains also known as lipid rafts (LR). LRs have been considered as pharmacological target of anti-aggregation drugs as they suggested providing a platform for physiological activity of target proteins such as purinergic receptors (P2XR, P2YR) activated by nucleotides (ATP and ADP respectively). Localization of P2XR in these microdomains remains mostly unknown. The aim of this study was to compare the effectivity of different conventional detergents for lipid rafts isolation and investigation on the lipidomics and proteomics features of these microdomains focusing their potentiality of containing P2XR. Obviously, given the lack of well-established methods for platelet membrane studies, we also aimed at comparing the effectivity of different conventional detergents studies of plasma membrane studies. Material and methods: Platelets were obtained from healthy donors from Etablissement Franc_ais du Sang. Platelets were lysed with three different detergents (Brij 35, lubrol and TritonX100) in low and high doses (0.05% and 1%). After density separation of platelets lysate using ultracentrifugation with sucrose gradient (5, 35 and 45%), 12 equal sucrose fractions were collected and concentration of cholesterol (Ch), sphingomyelin (SM) and phosphatidyl-choline (PC) were quantified. Based on these lipidomics results, fractions containing raft and nonraft domains were subjected to proteomics analysis. Results: LRs mainly were observed in fractions 1–4 in all detergents except Triton 0.05% that was not being able to extract lipid rafts. Ch and SM enrichment analysis were performed by Ch/PC and SM/PC ratio in each fraction. It showed that Lubrol 1% and Triton 1% were more suitable detergents as they were able to isolate raft fractions enriched in Ch and SM about 1.5 times more than other detergents (Lubrol 1%: Ch/PC = 1.52 and SM/PC= 1.44; Triton 1%: Ch/PC = 1.77 and SM/PC= 1.48). By proteomics analysis; overall 822 proteins were identified in platelet membrane. Each detergent revealed a different profile of protein’s set. P2XR was found only in fractions contain lipid rafts by Brij 1% and Lubrol 0.05%. Discussion / Conclusion: Investigating on P2XR on the membrane of platelets, Brij 1% and Lubrol 0.05% would be suitable detergents. Our results suggest that depending on the focal objective of study, adopting a compatible detergent has a great importance.

Published
2015

21. Identification of functional proteins related to Factor XIII in platelet lipid rafts

Author

Rabani, Vahideh, Montange, Damien, Gambert, Ségolène, Meneveau, Nicolas, Davani, Siamak, ProdInra, Archive Ouverte, Université de Franche-Comté (UFC), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre des Sciences du Goût et de l'Alimentation [Dijon] (CSGA), Institut National de la Recherche Agronomique (INRA)-Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique (CNRS), Université de Franche-Comté ( UFC ), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Centre des Sciences du Goût et de l'Alimentation [Dijon] ( CSGA ), Institut National de la Recherche Agronomique ( INRA ) -Université de Bourgogne ( UB ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique ( CNRS ), Université Bourgogne Franche-Comté [COMUE] (UBFC), and Centre National de la Recherche Scientifique (CNRS)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Institut National de la Recherche Agronomique (INRA)-Université de Bourgogne (UB)

Subjects
[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, [ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathology, [ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system
Abstract

absent

Published
2015

24. Impact of ticagrelor on P2Y1 and P2Y12 localization and on cholesterol levels in platelet plasma membrane.

Author

Rabani, Vahideh, Montange, Damien, Meneveau, Nicolas, and Davani, Siamak

Subjects
*BLOOD cholesterol, *PLATELET aggregation inhibitors, *BLOOD platelet activation, *ANTIBIOSIS, *CELL membranes, *CHOLESTEROL, *TICAGRELOR
Abstract

Ticagrelor is an antiplatelet agent that inhibits platelet activation via P2Y12 antagonism. There are several studies showing that P2Y12 needs lipid rafts to be activated, but there are few data about how ticagrelor impacts lipid raft organization. Therefore, we aimed to investigate how ticagrelor could impact the distribution of cholesterol and consequently alter the organization of lipid rafts on platelet plasma membranes. We identified cholesterol-enriched raft fractions in platelet membranes by quantification of their cholesterol levels. Modifications in cholesterol and protein profiles (Flotillin 1, Flotillin 2, CD36, P2Y1, and P2Y12) were studied in platelets stimulated by ADP, treated by ticagrelor, or both. In ADP-stimulated and ticagrelor-treated groups, we found a decreased level of cholesterol in raft fractions of platelet plasma membrane compared to the control group. In addition, the peak of cholesterol in different experimental groups changed its localization on membrane fractions. In the control group, it was situated on fraction 2, while in ADP-stimulated platelets, it was located in fractions 3 to 5, and in fraction 4 in ticagrelor-treated group. The proteins studied also showed changes in their level of expression and localization in fractions of plasma membrane. Cholesterol levels of plasma membranes have a direct role in the organization of platelet membranes and could be modified by stimulation or drug treatment. Since ticagrelor and ADP both changed lipid composition and protein profile, investigating the lipid and protein composition of platelet membranes is of considerable importance as a focus for further research in anti-platelet management. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

27. Duration: escalation study of oral etoposide with carboplatin in patients with varied solid tumors

Author

Thiery-Vuillemin, Antoine, primary, Dobi, Erion, additional, Nguyen, Thierry, additional, Royer, Bernard, additional, Montange, Damien, additional, Maurina, Tristan, additional, Kalbacher, Elsa, additional, Bazan, Fernando, additional, Villanueva, Cristian, additional, Demarchi, Martin, additional, Chaigneau, Loic, additional, Ivanaj, Arben, additional, and Pivot, Xavier, additional

Published
2010
Full Text
View/download PDF

30. Relative Impact of Ribavirin Monitoring and HIV Coinfection on Sustained Virological Response in Patients with Chronic Hepatitis C

Author

Piedoux, Sarah, Monnet, Elisabeth, Piroth, Lionel, Montange, Damien, Royer, Bernard, Thevenot, Thierry, Kantelip, Jean Pierre, Martino, Vincent Di, and Muret, Patrice

Abstract

Background In chronic hepatitis C, higher ribavirin (RBV) concentrations are associated with sustained virological response (SVR); target concentration cutoffs have been proposed. As RBV displays interindividual variability, monitoring of RBV plasma levels appears relevant. The impact of RBV therapeutic drug monitoring (TDMRBV) on SVR has not been explored in current practice. Our study aimed to assess this impact.Methods Three patient groups were defined as RBV cutoffs achieved at week 12 (group A1), not achieved (group A2), and one without RBV concentration assessment (group B). A predictive model assessed the group impact on SVR in multivariate analysis, while adjusting for additional predictive factors. A specific evaluation of HIV–HCV-coinfected patients was performed.Results A total of 122 patients were included. In group A1 (n=30, HIV-positive =18), SVR, relapse and non-response rates were 60%, 17% and 23%, respectively; in group A2 (n=32, HIV-positive =18), 25%, 19% and 56%, respectively; and in group B (n=60, HIV-positive =3), 52%, 33% and 15%, respectively (P=0.0004). The patient group was an independent predictor of SVR (P=0.01), along with baseline viral load and HCV genotype. HIV coinfection did not impede the SVR rate. The cutoffs were achieved in 62% and 28% (P=0.008) of patients, when TDMRBVwas performed or not, respectively.Conclusions The achievement of RBV cutoffs is a predictive factor of SVR independent of HIV coinfection. It makes it possible to reach high SVR rates, avoid relapse and obtain the same SVR rates in HIV–HCV-coinfected as in HCV-monoinfected patients. TDMRBVenables RBV concentration cutoffs to be reached more frequently and could thus be a useful tool to optimize hepatitis C treatment.

Published
2011
Full Text
View/download PDF

31. An APCI LCMSMS method for routine determination of capecitabine and its metabolites in human plasma

Author

Montange, Damien, Bérard, Michel, Demarchi, Martin, Muret, Patrice, Piédoux, Sarah, Kantelip, Jean Pierre, and Royer, Bernard

Abstract

The anticancer drug capecitabine and its metabolites including the active metabolite 5fluorouracil 5FU display high pharmacokinetic interpatient variability. Such variability, which may lead to treatment failure or toxicity, could need drug concentration measurement to individualize dosing regimen. However, usual assay methods are often long and fastidious. A simultaneous and costeffective method was thus developed for the determination of the concentrations of these compounds in human plasma. Compounds were extracted viaa classic liquid–liquid extraction. Chromatographic analysis was performed on a C18 reverse phase column with detection by atmosphere pressure chemical ionization LCMSMS. Our method allows a good chromatographic separation of the compounds and was fully validated following Food and Drug Administration FDA recommendations good selectivity, no carryover, linearity of the calibration curves without weighting, deviations from nominal concentrations of standard samples lower than 15, intra and interassay precision and accuracy lower than 15. Recovery and stability were also acceptable following the FDA guidelines. A matrix effect impairing the determination of 5FU was avoided by using a stable isotopic derivative of 5FU as internal standard. Interestingly, this method allows detection of TetraHydroUridine, an inhibitor of ex vivodegradation of metabolites, which is essential for the stability, the adequate conditioning of blood samples and for good laboratory practice, essential in routine determination. This method seems usable to routinely determine concentrations of capecitabine and its metabolites in blood and may be helpful in further studies aiming at performing therapeutic drug monitoring. Copyright © 2010 John Wiley & Sons, Ltd.

Published
2010
Full Text
View/download PDF

32. Initiating antiretroviral treatment early in infancy has long-term benefits on the HIV reservoir in late childhood and adolescence

Author

Avettand-Fenoel, Véronique, Lechenadec, Jérôme, Diallo, Mariama Sadjo, Fillion, Marine, Melard, Adeline, Samri, Assia, Dollfus, Catherine, Blanche, Stéphane, Faye, Albert, Amokrane, Kahina, Autran, Brigitte, Buseyne, Florence, Warszawski, Josiane, Frange, Pierre, Study, ANRS-EP59-CLEAC, Laboratoire de Microbiologie Clinique [AP-HP Hôpital Necker-Enfants Malades], CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Cité (UPCité), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Centre d'Immunologie et des Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service d'immuno-hématologie pédiatrique [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de pédiatrie générale, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré-Université Paris Cité (UPCité), Service d'Immunologie et d'Histocompatibilité, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Cité (UPCité), Epidémiologie et Physiopathologie des Virus Oncogènes / Oncogenic Virus Epidemiology and Pathophysiology (EPVO (UMR_3569 / U-Pasteur_3)), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Imagine - Institut des maladies génétiques (IHU) (Imagine - U1163), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), The ANRS CLEAC study was supported by the ANRS (French National Agency for Research on AIDS and Viral Hepatitis)., The ANRS CLEAC study group: Hôpital Armand Trousseau, Paris: Mary-France Courcoux, Catherine Dollfus, Marie-Dominique Tabone, Geneviève Vaudre, Hôpital Bicêtre, Le Kremlin-Bicêtre: Corinne Fourcade, Josiane Warsazawski, Jérôme Lechenadec, Olivia Dialla, Laura Nailler, Lamya Ait Si Selmi, Isabelle Leymarie, Thierry Wack, Alexandre Hoctin, Razika Feraon-Nanache, Centre hospitalier intercommunal de Créteil: Isabelle Hau, Hôpital Delafontaine, Saint-Denis: Cécile Gakobwa, Hôpital Necker-Enfants Malades, Paris: Véronique Avettand-Fenoël, Stéphane Blanche, Marine Fillion, Pierre Frange, Nizar Mahlaoui, Adeline Mélard,Florence Veber, Marie-Christine Mourey, Maternité Port-Royal, Paris: Valérie Marcou, Hôpital Robert Debré, Paris: Albert Faye, Martine Lévine, Sandrine Richard, Pitié-Salpêtrière, Paris: Brigitte Autran, Assia Samri, Mariama Diallo, Hôpital Saint-Louis: Sophie Caillat-Zucman, Kahina Amokrane, Rayna Ivanova-Derin, Centre hospitalier intercommunal de Villeneuve-Saint-Georges: Anne Chacé, Institut Pasteur Paris: Florence Buseyne, Thomas Montange, Damien Batalie, Ingrid Fert, Asier Saez-Cirion, Valérie Monceaux, Daniel Scott-Algara, ANRS: Lucie Marchand, Delphine Lebrasseur, Axel Levier., Université de Paris (UP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Centre d'Immunologie et de Maladies Infectieuses (CIMI), Service d'hématologie-immunologie-oncologie pédiatrique [CHU Trousseau], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré-Université de Paris (UP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université de Paris (UP), Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), and Buseyne, Florence

Subjects
[SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, [SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics, virus diseases, [SDV.MHEP.PED] Life Sciences [q-bio]/Human health and pathology/Pediatrics, early ART, children, HIV DNA, protective HLA, [SDV.IMM.IA]Life Sciences [q-bio]/Immunology/Adaptive immunology, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, [SDV.IMM.IA] Life Sciences [q-bio]/Immunology/Adaptive immunology, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, adolescents
Abstract

International audience; BackgroundEarly combined antiretroviral therapy (cART) limits the total HIV-DNA load in children. However, data on its impact in older children and adolescents remain scarce. This study aims to compare HIV reservoirs in children (5-12 years) and adolescents (13-17 years) who started cART before 6 months (early (E-)group) or after 2 years old (late (L-)group). MethodsThe ANRS-EP59-CLEAC study prospectively enrolled 76 HIV-1 perinatally-infected patients who reached HIV-RNA

Published
2021
Full Text
View/download PDF

33. The number of circulating CD14(+) cells is related to infarct size and postinfarct volumes in ST segment elevation myocardial infarction but not non-ST segment elevation myocardial infarction.

Author

Montange D, Davani S, Deschaseaux F, Séronde MF, Chopard R, Schiele F, Jehl J, Bassand JP, Kantelip JP, and Meneveau N

Abstract

Objective: To determine the relationship between the number of CD14(+) cells, myocardial infarct (MI) size and left ventricular (LV) volumes in ST segment elevation MI (STEMI) and non-ST segment elevation MI (NSTEMI) patients., Methods: A total of 62 patients with STEMI (n=34) or NSTEMI (n=28) were enrolled. The number of CD14(+) cells was assessed at admission. Infarct size, left ventricular ejection fraction (LVEF) and LV volumes were measured using magnetic resonance imaging five days after MI and six months after MI., Results: In STEMI patients, the number of CD14(+) cells was positively and significantly correlated with infarct size at day 5 (r=0.40; P=0.016) and after six months (r=0.34; P=0.047), negatively correlated with LVEF at day 5 (r=-0.50; P=0.002) and after six months (r=-0.46; P=0.005) and positively correlated with end-diastolic (r=0.38; P=0.02) and end-systolic (r=0.49; P=0.002) volumes after six months. In NSTEMI patients, no significant correlation was found between the number of CD14(+) cells and infarct size, LVEF or LV volumes at day 5 or after six months., Conclusions: The number of CD14(+) cells at admission was associated with infarct size and LV remodelling in STEMI patients with large infarct size, whereas in NSTEMI patients, no relationship was observed between numbers of CD14(+) cells and LV remodelling.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results